Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (XLO)

Historical Holders from Q4 2021 to Q3 2025

Symbol
XLO on Nasdaq
CUSIP
98422T100
Type / Class
Equity / Common Stock, par value $0.0001 per share
Shares outstanding
55.6M
All holders as of September 30, 2025
Q3 2025
Total 13F shares, excl. options
22.1M
Holdings value
$18.6M
% of all portfolios
0%
Grand Portfolio weight change
0%
Number of holders
36
Number of buys
10
Number of sells
-7
Average Value change %
0%
Average buys %
+0%
Average sells %
0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (XLO)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
GILEAD SCIENCES, INC. 19.9% 0% $7.32M $1.04M 10.6M +16.6% GILEAD SCIENCES, INC. Jun 30, 2025
Frazier Life Sciences Public Fund, L.P. 9.9% 0% $5.62M $1.65M 8.14M +41.7% Frazier Life Sciences Public Fund, L.P. Jun 30, 2025
Point72 Asset Management, L.P. 9.9% +38.6% $6.75M $3.38M 8M +100% Point72 Asset Management, L.P. Sep 30, 2025
AbbVie Inc. 9% $3.09M 4.35M AbbVie Inc. Feb 11, 2025
STEMPOINT CAPITAL LP 7.2% $3.38M 4M StemPoint Capital LP Sep 30, 2025

Institutional Holders of Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (XLO)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 22.1M $18.6M -$1.23M $0.84 36
2025 Q2 23.8M $16.2M +$854K $0.68 35
2025 Q1 22.5M $16.3M -$3.18M $0.72 35
2024 Q4 25.8M $24.7M -$145K $0.96 34
2024 Q3 15.9M $12.5M +$1.13M $0.79 32
2024 Q2 13M $12.3M +$1.79M $0.95 30
2024 Q1 12.5M $13.5M -$2.78M $1.08 30
2023 Q4 1.48M $811K $0.55 1
2023 Q3 15.9M $33.5M -$315K $2.11 30
2023 Q2 16M $41.9M -$192K $2.62 32
2023 Q1 16.1M $51M +$462K $3.17 32
2022 Q4 15.9M $42.8M -$711K $2.69 28
2022 Q3 16.6M $48.2M -$3.74M $2.91 26
2022 Q2 17.8M $52M -$2.93M $2.92 26
2022 Q1 18.8M $133M -$2.57M $7.07 41
2021 Q4 19M $303M +$259M $16.00 41